Dauricine |
Catalog No.GC38182
One-Click Copy Product Info
|
Dauricine is a bioactive alkaloid with anticancer properties extracted from Menispermum dauricum DC.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 524-17-4
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Dauricine is a bioactive alkaloid with anticancer properties extracted from Menispermum dauricum DC. Dauricine inhibits tumor cell proliferation and induces apoptosis by suppressing signaling pathways such as Hedgehog, PI3K/Akt, and Src/STAT3[1-2]. Dauricine is applicable for research in various cancers and Alzheimer's disease[3-4].
In vitro, PC9-OR and H1975-OR osimertinib-resistant lung cancer cell lines were co-treated with Dauricine (0-100μM) and osimertinib. Dauricine induced ferroptosis in the cells, significantly inhibiting their viability[5]. A549, H1299, A427, and LLC lung adenocarcinoma cells were treated with Dauricine (5–20μM) for 24–48 hours. Dauricine significantly inhibited cell proliferation and migration, induced cell cycle arrest at the G0/G1 phase, increased intracellular reactive oxygen species (ROS) levels, downregulated Nrf2 expression, and ultimately triggered apoptosis[6].
In vivo, nude mice bearing BxPC-3 pancreatic cancer xenografts were treated with daily intraperitoneal injections of Dauricine (6mg/kg and 12mg/kg) for 21 days. Dauricine significantly inhibited tumor growth without markedly affecting the spleen index[7]. Ten-week-old female C57BL/6J mice were treated with intraperitoneal injections of Dauricine (2.5mg/kg; every two days) in combination with LPS (5mg/kg; once a week) for 3 weeks. Dauricine significantly alleviated LPS-induced inflammatory bone loss[8].
References:
[1] Chen KQ, Wang SZ, Lei HB, et al. Dauricine: Review of Pharmacological Activity. Drug Des Devel Ther. 2024 Sep 27;18:4371-4385.
[2] Li L, Dai S, Liu JY, et al. Antagonistic Effect and In Vitro Activity of Dauricine on Glucagon Receptor. J Nat Prod. 2022 Aug 26;85(8):2035-2043.
[3] Zhang X, Wang T, Miao Y, et al. Dauricine exhibits anti-inflammatory property against acute ulcerative colitis via the regulation of NF-κB pathway. Cell Biochem Funct. 2023 Aug;41(6):713-721.
[4] Wang L, Pu Z, Li M, et al. Antioxidative and antiapoptosis: Neuroprotective effects of dauricine in Alzheimer's disease models. Life Sci. 2020 Feb 15;243:117237.
[5] Men B, Chen Z, Ge H, et al. Dauricine Overcomes Osimertinib Resistance in Lung Cancer by Inducing Ferroptosis via Stabilizing SAT1. Cancer Sci. 2025 Aug;116(8):2256-2269.
[6] Yousuf W, Siddiqui NZ, Ali P, et al. Dauricine Impedes the Tumorigenesis of Lung Adenocarcinoma by Regulating Nrf2 and Reactive Oxygen Species. Cells. 2025 May 12;14(10):698.
[7] Zhang YB, Fei HX, Guo J, et al. Dauricine suppresses the growth of pancreatic cancer in vivo by modulating the Hedgehog signaling pathway. Oncol Lett. 2019 Nov;18(5):4403-4414.
[8] Park HJ, Gholam Zadeh M, et al. Dauricine Protects from LPS-Induced Bone Loss via the ROS/PP2A/NF-κB Axis in Osteoclasts. Antioxidants (Basel). 2020 Jul 6;9(7):588.
| Cell experiment [1]: | |
Cell lines | A549, H1299, A427, and Lewis Lung Carcinoma (LLC) cells (lung adenocarcinoma cell lines) |
Preparation Method | A549 and H1299 cells were maintained in RPMI-1640 medium, A427 cells in Modified Eagles Medium (MEM), and LLC cells in Dulbecco's Modified Eagles Medium (DMEM), all supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin at 37°C, 5% CO₂. Cells were treated with Dauricine (5–20μM) for 24-48 hours |
Reaction Conditions | 5–20μM; 24-48 hours. |
Applications | Dauricine significantly inhibited the proliferation and migration of lung adenocarcinoma cells, induced cell cycle arrest at the G0/G1 phase, and markedly increased intracellular reactive oxygen species (ROS) levels. Dauricine also led to the downregulation of the redox regulator Nrf2 and altered the expression of apoptosis-related markers (decreased Bcl-2, increased BAX and cleaved Caspase 3). |
| Animal experiment [2]: | |
Animal models | 10-week-old female C57BL/6J mice |
Preparation Method | Mice were randomly assigned to four groups and treated via intraperitoneal injection for 3 weeks. Groups received: (1) vehicle control (PBS); (2) vehicle with Dauricine (2.5mg/kg, once every two days); (3) LPS (5mg/kg, once a week); (4) LPS with Dauricine. |
Dosage form | 2.5mg/kg; i.p.; once every two days for 3 weeks. |
Applications | Co-treatment with Dauricine significantly prevented LPS-induced bone loss, as evidenced by increased bone mineral density (BMD), bone volume (BV/TV), and trabecular thickness (Tb.Th), and decreased trabecular separation (Tb.Sp). Dauricine also reduced the number of osteoclasts (OC.N/BS), lowered serum levels of the bone resorption marker CTX-1, the inflammatory marker MCP-1, and reactive oxygen species (ROS) elevated by LPS. Dauricine alone did not induce significant differences compared to the vehicle control. |
References: | |
| Cas No. | 524-17-4 | SDF | |
| Canonical SMILES | OC1=CC=C(C[C@H]2N(C)CCC3=C2C=C(OC)C(OC)=C3)C=C1OC4=CC=C(C[C@H]5N(C)CCC6=C5C=C(OC)C(OC)=C6)C=C4 | ||
| Formula | C38H44N2O6 | M.Wt | 624.77 |
| Solubility | DMSO : 100 mg/mL (160.06 mM; Need ultrasonic) | Storage | 4°C, protect from light |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.6006 mL | 8.0029 mL | 16.0059 mL |
| 5 mM | 320.1 μL | 1.6006 mL | 3.2012 mL |
| 10 mM | 160.1 μL | 800.3 μL | 1.6006 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 28 reference(s) in Google Scholar.)